Accordingly, a human monoclonal antibody directed against sortilin is currently in clinical trials (19, 20, 21) to block sortilin-mediated PGRN clearance in subjects at risk for or with FTD due to PGRN deficiency caused by heterozygous mutations in the GRN gene (15, 16). Here, GRN is linked to frontotemporal dementia.